Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Silence Therapeutics Plc ADR (NQ: SLN ) 19.65 +0.45 (+2.34%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Silence Therapeutics Plc ADR < Previous 1 2 Next > Analyst Expectations For Silence Therapeutics's Future August 16, 2024 Via Benzinga SLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024 August 15, 2024 Silence Therapeutics just reported results for the second quarter of 2024. Via InvestorPlace The 3 Best Gene Editing Stocks to Buy in August 2024 August 07, 2024 These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases. Via InvestorPlace Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks July 25, 2024 It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it. Via InvestorPlace The Analyst Landscape: 6 Takes On Silence Therapeutics June 20, 2024 Via Benzinga What 7 Analyst Ratings Have To Say About Silence Therapeutics May 17, 2024 Via Benzinga Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock April 22, 2024 Via Benzinga What 4 Analyst Ratings Have To Say About Silence Therapeutics March 13, 2024 Via Benzinga Where Silence Therapeutics Stands With Analysts August 17, 2023 Via Benzinga What 6 Analyst Ratings Have To Say About Silence Therapeutics June 26, 2023 Via Benzinga SLN Stock Earnings: Silence Therapeutics Reported Results for Q1 2024 May 16, 2024 Silence Therapeutics just reported results for the first quarter of 2024. Via InvestorPlace 3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024 April 11, 2024 Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one. Via InvestorPlace 7 Biotech Stocks Ready to Ride the Sector’s Resurgence March 18, 2024 With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. Via InvestorPlace These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results March 14, 2024 Silence Therapeutics Plc (NASDAQ: SLN) reported a loss for 2023 on Wednesday. Via Benzinga What's Going On With Silence Therapeutics Stock Today? March 13, 2024 Silence Therapeutics reports narrower Q4 loss, data from zerlasiran study, and strengthened cash position. In March 2024, Mallinckrodt notified Silence that they will not pursue further development of... Via Benzinga The Latest Analyst Ratings for Silence Therapeutics May 11, 2023 Via Benzinga Earnings Scheduled For March 13, 2024 March 13, 2024 Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. Via Benzinga Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday January 31, 2024 U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday. Via Benzinga Topics Stocks Exposures US Equities Earnings Scheduled For March 12, 2024 March 12, 2024 Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter. Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session December 13, 2023 Via Benzinga Is This A Miracle Drug For 'Sticky Cholesterol'? Analysts Applaud Safety, Efficacy Of Silence Therapeutics' Heart Disease Candidate November 01, 2023 Earlier today, Silence Therapeutics plc (NASDAQ: SLN) announced topline results from the multiple-dose component of the APOLLO phase 1 study of zerlasiran (formerly SLN360) in 36 adults with baseline... Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session November 01, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023 May 08, 2023 Via Benzinga Earnings Scheduled For August 10, 2023 August 10, 2023 Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. Via Benzinga Stocks That Hit 52-Week Lows On Tuesday April 25, 2023 Tuesday's session saw 286 companies set new 52-week lows. Via Benzinga Stocks That Hit 52-Week Lows On Monday April 24, 2023 On Monday, 147 stocks made new 52-week lows. Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session April 17, 2023 Via Benzinga Stocks That Hit 52-Week Lows On Wednesday March 29, 2023 On Wednesday, 81 companies hit new 52-week lows. Via Benzinga Stocks That Hit 52-Week Lows On Friday April 21, 2023 During Friday's session, 149 stocks hit new 52-week lows. Via Benzinga Earnings Scheduled For March 15, 2023 March 15, 2023 Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million. Via Benzinga < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.